As shown in Tables 1 and 2, in both the TCGA and METABRIC cohorts, expression of ICOS is associated with molecular and clinical characteristics including age, tumor stage, estrogen receptor (ER) status, progestogen receptor (PR), HER2 status, and tumor grade. This evidence concerns the gene ESR1 and neoplasm.